PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.52 - 1.58
1.19 - 3.37
354.5K / 984.1K (Avg.)
-1.64 | -0.94
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
35.46%
Revenue growth above 1.5x CSIQ's 21.55%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
-171.55%
Negative gross profit growth while CSIQ is at 36.77%. Joel Greenblatt would examine cost competitiveness or demand decline.
-922.43%
Negative EBIT growth while CSIQ is at 175.08%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-930.10%
Negative operating income growth while CSIQ is at 125.31%. Joel Greenblatt would press for urgent turnaround measures.
-948.31%
Negative net income growth while CSIQ stands at 361.91%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-946.15%
Negative EPS growth while CSIQ is at 356.52%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-943.59%
Negative diluted EPS growth while CSIQ is at 359.09%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.00%
Share reduction more than 1.5x CSIQ's 0.16%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
0.07%
Diluted share reduction more than 1.5x CSIQ's 4.47%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
279.96%
OCF growth of 279.96% while CSIQ is zero. Bruce Berkowitz would see if small gains can expand into a larger competitive lead.
19.65%
FCF growth of 19.65% while CSIQ is zero. Bruce Berkowitz would see if modest improvements in free cash can accelerate further.
58.55%
10Y revenue/share CAGR under 50% of CSIQ's 305.90%. Michael Burry would suspect a lasting competitive disadvantage.
-17.44%
Negative 5Y CAGR while CSIQ stands at 178.00%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-46.77%
Negative 3Y CAGR while CSIQ stands at 9.36%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
23.68%
10Y OCF/share CAGR under 50% of CSIQ's 100.00%. Michael Burry would worry about a persistent underperformance in cash creation.
-71.13%
Negative 5Y OCF/share CAGR while CSIQ is at 100.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
-63.14%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-6403.77%
Negative 10Y net income/share CAGR while CSIQ is at 378.12%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-234.35%
Negative 5Y net income/share CAGR while CSIQ is 143.24%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-497.53%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
-91.06%
Negative equity/share CAGR over 10 years while CSIQ stands at 281.45%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-87.75%
Negative 5Y equity/share growth while CSIQ is at 162.31%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-91.23%
Negative 3Y equity/share growth while CSIQ is at 35.84%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2.19%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
-13.57%
Inventory is declining while CSIQ stands at 14.78%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-15.77%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-74.09%
We have a declining book value while CSIQ shows 6.76%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-24.22%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-4.20%
Our R&D shrinks while CSIQ invests at 17.78%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
6.03%
SG&A declining or stable vs. CSIQ's 13.96%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.